Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO) Six-month echocardiographic follow-up by Hanna, Ibrahim R. et al.
L
A
A
S
I
M
A
A
a
v
s
e
r
g
e
c
(
a
t
p
w
a
v
a
r
f
a
A
R
1
Journal of the American College of Cardiology Vol. 43, No. 10, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2003.12.050eft Atrial Structure and Function
fter Percutaneous Left Atrial
ppendage Transcatheter Occlusion (PLAATO)
ix-Month Echocardiographic Follow-Up
brahim R. Hanna, MD,* Paul Kolm, PHD,* Randolph Martin, MD, FACC,*
ark Reisman, MD, FACC,† William Gray, MD, FACC,† Peter C. Block, MD, FACC*
tlanta, Georgia; and Seattle, Washington
OBJECTIVES This study was designed to evaluate the effects of percutaneous left atrial appendage
transcatheter occlusion (PLAATO) on the anatomic and hemodynamic properties of the
mitral valve (MV) and left upper pulmonary vein (LUPV).
BACKGROUND PLAATO is a device designed to seal the neck of the left atrial (LA) appendage and reduce
embolization in patients with atrial fibrillation intolerant of warfarin. The impact of
deployment of this device on adjacent structures has not been reported.
METHODS Patients with atrial fibrillation participating in the ongoing study for evaluation of PLAATO
were enrolled. Transesophageal echocardiographies at baseline, one, and six months were
reviewed to measure LA and LUPV dimensions, degree of mitral regurgitation, stability of
the device, peak MV E-wave velocity, and peak systolic and diastolic flow velocities in the
LUPV. Data were analyzed by a linear mixed model for repeated measures.
RESULTS Eleven patients (mean age of 72  7 years) completed six months of follow-up. Left upper
pulmonary vein diameter (mean: 1.55, 1.61, 1.54 cm, p 0.13) and peak systolic (mean: 0.38,
0.34, 0.31 m/s, p  0.72) and diastolic flow velocities (mean: 0.39, 0.40, 0.42 m/s, p  0.46)
did not differ over the follow-up period. Left atrial size, mitral regurgitation severity, and MV
peak E-wave velocities (mean: 0.94, 0.94, 0.82 m/s, p  0.58) showed no significant change
from baseline. The devices remained stable at their sites of deployment with minimal residual
flow around them.
CONCLUSIONS PLAATO achieved an adequate seal of the neck of the left atrial appendage without
significant effect on the structure or function of the LA and LUPV. (J Am Coll Cardiol
2004;43:1868–72) © 2004 by the American College of Cardiology Foundationa
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Ptrial fibrillation (AF) is a major determinant of mortality
nd stroke, especially in older patients and those with left
entricular dysfunction, hypertension, diabetes, or prior
troke(s) (1,2). Over the past decade researchers have
valuated a variety of pharmacologic therapies aimed at
educing this risk. Oral anticoagulation with warfarin tar-
eting an international normalized ratio (INR) of 2 to 3 has
merged as preferred therapy, providing an acceptable
ompromise between stroke prevention and bleeding risk
3–9). Despite evidence supporting its use, warfarin is
pproached with caution for real or perceived contraindica-
ions (10). Recently, a novel mechanical approach for the
revention of cardioembolic strokes in high-risk patients
ith AF has been introduced: the percutaneous left atrial
ppendage (LAA) transcatheter occlusion (PLAATO) de-
ice seals the communication between the left atrium (LA)
nd its appendage. Initial animal testing (11), and more
ecently human feasibility data (12), have suggested success-
ul occlusion and stroke prevention. However, the anatomic
nd hemodynamic effects of PLAATO on the LA and its
From the *Division of Cardiology, Department of Medicine, Emory University,
tlanta, Georgia; and †Swedish Cardiovascular Research, Seattle, Washington. Dr.
eisman is a consultant for ev3.
Manuscript received November 25, 2003; revised manuscript received Decembert7, 2003, accepted December 23, 2003.djacent structures have not been reported. We studied six
onths’ echocardiographic follow-up of patients enrolled in
he PLAATO feasibility trial, with particular attention to
he impact of the device on the structure and function of the
itral valve (MV) and the left upper pulmonary vein
LUPV).
ETHODS
tudy population. The study population is part of the
ohort of patients enrolled in the ongoing multicenter
easibility trial evaluating PLAATO for prevention of
hromboembolism in AF. Patients with contraindication to
arfarin use, including cerebral or gastrointestinal bleeding,
hronic severe liver disease, unstable INR, or reluctance to
ake oral anticoagulation, were recruited if they had two or
ore of the following risk factors for stroke: age 65 years,
iabetes mellitus, hypertension, prior transient ischemic
ttack or stroke, congestive heart failure, or spontaneous
chocardiographic contrast in the LA by transesophageal
chocardiography (TEE). Patients with TEE evidence of
AA thrombus or atrial septal abnormalities (patent fora-
en ovale, atrial septal defect) were excluded. The
LAATO device was positioned transseptally in the neck ofhe LAA under TEE and fluoroscopic guidance. Implant
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May 19, 2004:1868–72 PLAATO and Left Atrial Structure and Functionize was chosen to achieve complete sealing of the append-
ge from the LA cavity as judged by the operator.
Twelve of 45 U.S. patients had completed their six
onths’ echocardiographic follow-up as of May 2003 and
ere included in the study. These patients were enrolled at
mory University Hospital and the Swedish Hospital.
leven of 12 patients were included in this analysis. One
atient was excluded because of limited echocardiographic
mages precluding accurate measurements.
chocardiographic parameters. Baseline parameters were
btained before device implantation. The size of the LA was
easured in the antero-posterior and cranio-caudal planes
ith the TEE probe at 0° and 120°, respectively, with the
argest dimension reported. The diameter of the LUPV was
easured at or near its site of insertion into the LA opposite
he largest diameter of the device. Flow across the MV was
ssessed by color Doppler to grade the degree of mitral
egurgitation (1 to 4 by a single observer) and by
ulse-wave Doppler to determine peak mitral E-wave ve-
ocity. Peak systolic and diastolic flows in the LUPV were
easured using pulse-wave Doppler. After successful de-
loyment of the device these parameters were remeasured.
atients were prescribed aspirin (325 mg daily) indefinitely
nd clopidogrel (75 mg daily) for four to six weeks.
Table 2. Baseline Measurements
Patient
HR
(beats/min)
LA
Size*
(cm)
MV
E-Wave†
(m/s)
1 95 5.64 1.38
2 88 5.66 1.01
3 70 4.78 0.93
4 90 4.29 0.93
5 63 7.21 0.95
6 84 6.7 0.62
7 73 5.64 0.21
8 81 7.34 0.96
9 93 7.26 0.95
10 67 5.2 0.86
11‡ 60 6.2 N/A
Each of the values reported in the table was averaged ov
antero-posterior) reported. †Peak velocity measured by puls
measurements.
HR  heart rate; LA  left atrium; LUPV  left upper
Abbreviations and Acronyms
AF  atrial fibrillation
INR  international normalized ratio
LA  left atrium
LAA  left atrial appendage
LUPV  left upper pulmonary vein
MR  mitral regurgitation
MV  mitral valve
PLAATO  percutaneous left atrial appendage
transcatheter occlusion
TEE  transesophageal echocardiographyN/A  not available.All patients were scheduled for repeat TEE at one and six
onths to assess stability of the device and healing of the
AA and to remeasure LUPV diameter and flow parame-
ers, as well as MV anatomy and flow parameters. In view of
nderlying AF, each measured parameter at any of the
ollow-up time points was reported as the average of
easurements made over four to six cardiac cycles.
tatistical analysis. The data were analyzed by a linear
ixed model for repeated measures. Heart rate, MV peak
-wave velocity, LUPV peak systolic wave (S-wave), and
eak diastolic wave (D-wave) velocities were modeled as a
unction of follow-up time from baseline to six months,
here follow-up time was included in the model as a fixed
actor.
able 1. Baseline Patient Characteristics
Patient
Age
(yrs) Gender
Duration
of Atrial
Fibrillation Stroke Risk Factors
1 74 Male  1 yr hypertension, diabetes
mellitus
2 69 Female  1 yr hypertension, diabetes
mellitus, prior stroke
3 76 Male  1 yr congestive heart failure
4 62 Male  1 yr hypertension, congestive
heart failure
5 74 Male  1 yr hypertension
6 71 Female  1 yr hypertension, prior
stroke, congestive
heart failure
7 65 Female  1 yr hypertension, prior
stroke
8 82 Male  1 yr hypertension, prior
stroke, congestive
heart failure
9 69 Male  1 yr hypertension
10 85 Female  1 yr hypertension, prior
stroke
11 67 Male  1 yr congestive heart failure
UPV
ameter
(cm)
LUPV
S-Wave†
(m/s)
LUPV
D-Wave†
(m/s)
MR
Severity
1.78 0.19 0.39 moderate
1.48 0.23 0.34 mild
1.46 0.21 0.5 moderate
1.5 0.21 0.31 trace
1.88 0.49 0.21 mild
1.25 0.36 0.41 trace
1.64 0.35 0.17 trace
1.59 0.34 0.37 trace
1.34 0.36 0.49 trace
1.43 0.23 0.94 mild
1.73 0.53 0.66 mild
to 6 cardiac cycles. *Largest dimension (cranio-caudal or
Doppler. ‡Patient was in normal sinus rhythm at time of
nary vein; MR  mitral regurgitation; MV  mitral valve;L
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aseline. Occlusion of the LAA was successful in the 11
atients studied (Table 1), with follow-up data available for
ost study parameters at one and six months. The average
ge of the patients was 72  7 years. Seven of the 11
atients were men. Ten patients had chronic AF of more
han one year’s duration, whereas one patient had been
iagnosed with AF less than a year before PLAATO
nsertion. This patient was in normal sinus rhythm at
aseline and at six months. One patient had a single-lead
ermanent pacemaker for complete atrioventricular node
lock and had a ventricular paced rhythm at all study time
oints. Mitral regurgitation (MR) was estimated by color
oppler as moderate in two patients, mild in four, and trace
n five. Minimal residual flow around the device as deter-
ined by color Doppler was noted in all patients in the
bsence of fluoroscopically detectable leak, and these find-
ngs were considered to represent satisfactory placement of
he device. Baseline and immediate postimplantation mea-
urements were identical for all study parameters (data not
hown), and only the baseline values were used for statistical
nalysis (Table 2).
Table 3. One-Month Measurements
Patient
HR
(beats/min)
MV
E-Wave*
(m/s)
L
D
1 95 1.16
2 75 1.09
3 72 0.6
4 85 0.82
5 66 0.99
6 105 N/A
7 75 N/A
8 71 N/A
9 98 N/A
10 75 0.95
11†
Each of the values reported in the table was averaged over 4 t
†One-month follow-up data not available.
Abbreviations as in Table 2.
Table 4. Six-Month Measurements
Patient
HR
(beats/min)
MV
E-Wave*
(m/s)
L
D
1 77 1.26
2 100 1.17
3 70 N/A
4 75 N/A
5 67 0.71
6 72 1.06
7 66 0.13
8 70 0.1
9 103 1.17
10†
11 73 0.99
Each of the values reported in the table was averaged over 4 t
†Data not available.Abbreviations as in Table 2.ollow-up (Tables 3 and 4). At one month the device was
table in all but one patient, whose device appeared to have
ilted slightly into the LA. The seal around the neck of the
AA was not compromised. In all patients there was
inimal residual flow around PLAATO by color Doppler
n a pattern similar to that observed immediately after device
lacement. No masses or thrombi were noted on the atrial
urface of the implanted devices (Fig. 1). The severity of
R was unchanged. At six months, no further changes in
mplant position were noted. The LA surface of the device
ppeared smooth, with no irregular trailing edges, and the
AA distal to the device was thrombosed without evidence
f detectable flow distal to the device (Fig. 1). The degree of
R and the amount of flow around PLAATO were also
nchanged from baseline (Fig. 1).
Importantly, there was no significant difference from base-
ine to six months for any of the variables measured (Table 5).
ISCUSSION
arfarin has been shown to reduce the risk of thrombo-
mbolism in patients with AF at the expense of an increased
er
LUPV
S-Wave*
(m/s)
LUPV
D-Wave*
(m/sec)
MR
Severity
0.18 0.36 moderate
0.29 0.51 mild
0.15 0.4 moderate
0.25 0.34 trace
0.87 0.28 mild
0.25 0.36 trace
0.46 0.13 trace
N/A N/A trace
N/A N/A trace
0.28 0.79 mild
diac cycles. *Peak velocity measured by pulse-wave Doppler.
er
LUPV
S-Wave*
(m/s)
LUPV
D-Wave*
(m/s)
MR
Severity
0.18 0.36 moderate
0.22 0.59 mild
0.18 0.36 moderate
0.13 0.39 trace
0.45 0.21 mild
N/A N/A trace
0.42 0.15 trace
0.31 0.47 trace
0.43 0.62 trace
0.51 0.67 mild
diac cycles. *Peak velocity measured by pulse-wave Doppler.UPV
iamet
(cm)
1.66
1.56
1.57
1.67
1.94
1.46
1.67
1.56
N/A
1.39
o 6 carUPV
iamet
(cm)
1.59
1.54
1.57
1.46
1.86
1.25
1.56
1.54
1.35
1.68
o 6 car
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May 19, 2004:1868–72 PLAATO and Left Atrial Structure and Functionigure 1. Immediate postimplant (A) and six months (B) transesophageal echocardiographies showing the left atrium (LA), left upper pulmonary vein
LUPV), mitral valve (MV), and percutaneous left atrial appendage transcatheter occlusion (P). Flow in the LUPV showed no turbulence (double arrow).
he atrial surface of the device remained smooth. Residual flow around the device was noted at implantation and persisted at six months without change
single arrow). Clot/fibrosis of the left atrial appendage was clearly seen at six months (*).
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PLAATO and Left Atrial Structure and Function May 19, 2004:1868–72ncidence of bleeding. Bleeding, falls, difficult-to-control
NR levels, and personal preference preclude the use of oral
nticoagulation in some patients. Because the LAA is the
ource of cardiac emboli in 90% of patients with nonrheu-
atic AF in whom an intracardiac thrombus has been
isualized (13), exclusion of the LAA from the circulation is
n alternative for the prevention of strokes in high-risk
atients with AF and contraindication for long-term anti-
oagulation. Recently published data evaluating the
LAATO device have demonstrated the feasibility of this
pproach, and the successful prevention of thromboemboli
n the 15 patients studied (12). One concern, however, is
hat the deployment of a foreign body in the neck of the
AA and the resulting thrombosis/fibrosis of the appendage
ight deleteriously affect LA structure and function. Close
roximity of the device to the LUPV and the MV could
esult in pulmonary vein stenosis or impairment of mitral
eaflet excursion. Our study shows that PLAATO has little
f any impact on the structural and functional integrity of
he LUPV and the MV. At six months, none of the
easured parameters showed significant changes from base-
ine. Given the stability of the device and the complete
ealing of the LAA over that time period, the data analyzed
t six months are likely to represent long-term behavior of
he device. Furthermore, PLAATO was incorporated in the
A without thrombosis on the atrial surface, likely the
esult of successful neoendocardial formation. Interestingly,
ll patients had minimal flow around PLAATO immedi-
tely after implantation and at follow-up, but this commu-
ication between LA and LAA did not preclude thrombo-
is/fibrosis of the distal LAA. Even in the patient in whom
he device tilted slightly into the body of the LA during the
rst month after implantation, the displacement did not
rogress and the seal of the LAA remained preserved. This
tudy was not designed to evaluate the effect of PLAATO
n stroke risk, precluding an assessment of the impact of the
esidual flow seen by color Doppler on clinical end points.
In conclusion, these data show that the implantation of
he PLAATO device in the neck of the LAA does not result
n any detrimental anatomic or physiologic changes to
djacent structures over six months of follow-up. The device
s stable without thrombus formation on its atrial surface.
Table 5. Impact of PLAATO on MV and LU
Baseline
Mean  SD
(n)
Heart rate (beats/min) 78.5  12.5 (11)
LUPV diameter (cm) 1.55  0.19 (11)
MV E-wave* (m/s) 0.94  0.35 (10)
LUPV S-wave* (m/s) 0.38  0.22 (11)
LUPV D-wave* (m/s) 0.39  0.14 (10)
*Peak velocity measured by pulse-wave Doppler
Abbreviations as in Table 2.cknowledgments
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ne Month
ean  SD
(n)
Six Months
Mean  SD
(n)
p
Value
7  13.3 (10) 77.3  13.2 (10) 0.584
1  0.16 (9) 1.54  0.17 (10) 0.13
4  0.20 (6) 0.82  0.47 (8) 0.581
4  0.23 (8) 0.31  0.14 (9) 0.716
0  0.19 (8) 0.42  0.18 (9) 0.463PV S
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